Plant and Yeast Material
Arabidopsis thaliana accession Columbia (Col-0) was grown under a 9-hour photoperiod at 24ºC. Crude Col-0 protein extract was isolated as described previously (2) . One hundred liters of Saccharomyces cerevisiae BY4730 were grown in a fermentor in YPD media at 28ºC to a density of OD 600 = 2, centrifuged at 2,000 x g, and the resulting cakes were flash-frozen in liquid nitrogen.
Recombinant Protein Expression and Purification
Recombinant AvrRpt2 and mutant AvrRpt2(C122A) proteins containing an N-terminal polyhistidine tag and a C-terminal HA tag were overexpressed in E. coli BL21(DE3)pLysS using the protein expression vector pRSET (Invitrogen). Recombinant AvrRpt2 proteins were extracted under denaturing conditions using 6 M urea and purified by Ni + -sepharose and gel filtration chromatography with a pharmacia GP 250 fast-performance liquid chromatography system. E. coli clones were grown in LB medium containing 50 µg/mg carbenicillin and 35 µg/mg chloramphenicol to a density of OD 600 =0.4. Protein expression was induced overnight at 37ºC with 0.5 mM isopropyl ß-D-thioglactopyranoside (IPTG). Cells were lysed in a buffer containing 6 M urea, 10 mM imidazole, 100 mM HEPES, 10 mM sodium bisulfite, 10 mM sodium metabisulfite, 500 mM NaCl, and 10% glycerol supplemented with 1 mM phenylmethylsulfonylfluoride (PMSF), 1 mM leupeptin, and 2 mM ß-mercaptoethanol (pH 7.5). Recombinant AvrRpt2 and mutant AvrRpt2(C122A) proteins were purified by Ni + -sepharose affinity chromatography (Qiagen), renatured and refolded while immobilized on the nickel column using a linear 6 M to 0 M urea gradient over a 2 h period, and eluted with 250 mM imidazole. Recombinant proteins underwent a final purification step over a HiPrep 16/60 sephacryl 200 high resolution gel filtration column (GE Healthcare) in a buffer containing 100 mM HEPES, 10 mM sodium bisulfite, 10 mM sodium metabisulfite, 500 mM NaCl, 10% glycerol, and 2 mM ß-mercaptoethanol (pH 7.5). Protein concentrations were determined by Coomassie blue staining of SDS-PAGE gels using BSA standards.
Recombinant RIN4, CPR1, ROC1, and ROC7 proteins were expressed in E. coli BL21(DE3)pLysS and isolated under native conditions. E. coli clones were grown in LB medium containing 50 µg/mg carbenicillin and 35 µg/mg chloramphenicol to a density of OD 600 =0.4. Protein expression was induced for 4 h at 28ºC with 0.5 mM IPTG. Cells were lysed in a buffer containing 10 mM imidazole, 20 mM Tris pH 8, 500 mM NaCl, and 10% glycerol supplemented with 1 mM PMSF, 1 mM leupeptin, and 2 mM ß-mercaptoethanol. Proteins were purified by Ni + -sepharose affinity chromatography and eluted with 250 mM imidazole in the same buffer. Recombinant proteins underwent a final gel filtration purification step as described above. Protein concentrations were determined by Coomassie blue staining of SDS-PAGE gels using BSA standards.
Biochemical Purification of the AvrRpt2 Activator
Soluble S. cerevisiae BY4730 proteins were extracted from 50 g of frozen cells as described by (3) . S. cerevisiae proteins were separated over a HiTrap phenyl sepharose hydrophobic interaction column with a salt gradient from 1 M to 0 M (NH 4 ) 2 SO 4 (GE Healthcare). Individual fractions were assayed for their ability to enable AvrRpt2 N-terminal processing. Fractions possessing the majority of activity were pooled and dialyzed overnight at 4ºC against 3 L of buffer containing 20 mM diethanolamine, 10 mM MgCl 2 , 1 mM EDTA, 1 mM DTT, 5% glycerol, 1 mM PMSF, 1 mM leupeptin, pH 8.4. After dialysis, S. cerevisiae proteins were separated over a HiTrap Q sepharose anion exchange column with a salt gradient from 0 M to 0.5 M NaCl (GE Healthcare). Individual fractions retaining the ability to enable AvrRpt2 Nterminal processing were pooled, concentrated to 1 mL using an Amicon ultra-15 centrifugal filter device (Millipore). Positive fractions were then separated over a HiPrep 16/60 sephacryl 200 high resolution gel filtration column (GE Healthcare). Proteins in this final purification step contained in the positive fractions were separated by SDS-PAGE and visualized with a colloidal Coomassie blue stain (Invitrogen).
Protein Sequencing by Mass Spectrometry
Following Coomassie staining and destaining, protein bands to be sequenced were excised and prepared for mass spectrometry as described by (4) . An ABI 4700 MALDI tandem time-of-flight mass spectrometer (Applied Biosystems) was used for protein identification by means of peptide mass fingerprinting and MS/MS peptide sequencing.
AvrRpt2 and RIN4 Cleavage Reactions
For cleavage reactions of AvrRpt2 proteins in crude extract, purified recombinant AvrRpt2:HA or mutant AvrRpt2:HA(C122A) protein (2 µg) was incubated with 100 µg of crude Col-0 extract or 100 µg of crude S. cerevisiae BY4730 extract in a total volume of 50 µL in buffer containing 100 mM HEPES, 10 mM sodium bisulfite, 10 mM sodium metabisulfite, 2 mM ß-mercaptoethanol, and 1 mM PMSF (pH 7.5) for 15 h at 25°C. To assess the ability of AvrRpt2 to N-terminally process using purified column chromatography fractions during the biochemical purification of CPR1, purified recombinant AvrRpt2:HA (2 µg) was incubated with 20 µl of each fraction in a total volume of 50 µL. AvrRpt2:HA and mutant AvrRpt2:HA(C122A) proteins (2 µg) were incubated with 1 µg of purified recombinant CPR1, ROC1, or ROC7 protein in a total volume of 50 µL. For inhibition of cleavage using pharmacological reagents, each reaction was supplemented with 10 µM of cyclosporin A or rapamycin (Sigma). Proteins in 2 µL of each reaction were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The resulting blots were probed with anti-HA monoclonal antibody (Sigma) or polyclonal anti-AvrRpt2 antibody.
For identification of AvrRpt2 and RIN4 cleavage sites by mass spectrometry, 53 µg of recombinant AvrRpt2:HA, AvrRpt2:HA(C122A), and RIN4 proteins were added to 15 µg of ROC1 for 5h at 25°C. Proteins were resolved by SDS-PAGE and visualized by Coomassie blue staining.
AvrRpt2 Processing in S. cerevisiae
In order to express AvrRpt2 inside S. cerevisiae cyclophilin mutants, the yeast pESC expression vector (Stratagene) was modified to include the hygromycin dominant drug resistance marker for selection of transformants. First, AvrRpt2 and AvrRpt2(C122A) were cloned into pESC -TRP NotI/BglI sites under the Gal10 promoter. Next, the hygromycin resistance gene under control of the TEF promoter and terminator was released from the yeast E. coli shuttle vector pAG26 (5) by NotI digestion, blunt-ended with T4 DNA polymerase, and ligated into pESC -TRP digested with EcoRV to create pESC hyg. To determine if the Arabidopsis cyclophilin ROC1 could enable AvrRpt2 processing in mutant S. cerevisiae lines, ROC1 with a C-terminal FLAG tag was cloned into pESC hyg SalI/XhoI sites under the Gal1 promoter using primers 13 and 14. pESC hyg containing AvrRpt2 and AvrRpt2 co-expressed with ROC1:FLAG were transformed into S. cerevisiae strains KDY98.4a (MATa, ∆cpr1::LEU2, ∆cpr2::TRP1, ∆cpr3::HIS3, ∆cpr4::URA4, ∆cpr5::LEU2, ∆cpr6::G418, ∆cpr7::G418, ∆cpr8::MET15, ∆fpr1::ADE2, ∆fpr2::URA3, ∆fpr3::URA3, ∆fpr4::G418), KDY75.3b (MATa, ∆cpr1::LEU2, ∆cpr6::G418, ∆cpr7::G418, ∆fpr1::ADE2), and BY4730 using the lithium acetate method (6, 7). Construction of S. cerevisiae strains KDY98.4a and KDY75.3b are described in (7) . Before plating transformants on YPD plates supplemented with 300 µg/ml hygromycin B (Calbiochem-Novabiochem Co.), the cells were grown for 2 h in YPD at 30°C on a rotator to allow for expression of the hygromycin drug resistance marker. Single transformants were then inoculated into synthetic galactose minimal media and incubated for 16-20 h at 30°C to allow for AvrRpt2 expression. Two mL of each culture was then centrifuged at 10,000 x g and the pellet re-suspended in 100 µL of 1X SDS-PAGE sample buffer. Proteins in 10 µL of each reaction were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The resulting blots were probed with polyclonal anti-AvrRpt2 antibody.
In vitro Protein Binding Assays
IPTG-induced E. coli BL21(DE3)pLysS carrying GST:ROC1 and GST were collected and resuspended in TEN100 (20mM Tris, pH 7.4, 0.1mM EDTA, and 100mM NaCl). Bacteria were lysed by sonication and centrifuged twice for 15 min at 27,000 x g. GST:ROC1 and GST were immobilized on glutathione-sepharose beads by incubation with G beads (Pharmacia Biotech) pre-washed with TEN100 for 1h at 4°C. G beads were washed 4x with 100 volumes of TEN100 to remove unbound material. Binding reactions used 4 µg of recombinant AvrRpt2:HA or AvrRpt2:HA(C122A) with 15 µL of G beads coupled to GST:ROC1 or GST. Reactions were incubated at 4°C for 1 h with gentle shaking. G beads were then pelleted by centrifugation and washed 5x in 1 mL NTEN300 buffer (0.5% NP40, 0.1mM EDTA, 20mM Tris, pH 7.4, 300mM NaCl). Proteins bound to the G beads were recovered by boiling 5 min in 60 µL of 1X SDS sample buffer. Proteins in 10 µL of each reaction were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. The resulting blots were probed with anti-GST polyclonal antibody (GE Healthcare) and monoclonal anti-HA antibody (Sigma). Figures   FIGURE S1 . Identification of CPR1. CPR1 was excised from a 15% colloidal Coomassie blue stained SDS-PAGE gel, subjected to an in-gel trypsin digest, and identified by MALDI-TOF mass spectrometry. The graph is a mass spectrum of the peptides detected, where m/z indicates the mass-to-charge ratio, T indicates tryptic autolysis peptides, and * indicates a peptides whose m/z ratio matched a CPR1 tryptic peptide. Labeled m/z values are monoisotopic MH + masses. Amino acid sequences determined or verified by means of tandem mass spectrometry are indicated next to the m/z of the peptide. (Fig 3C) . Fragment 2 comprises the N-terminus of RIN4 up to site I (underlined in red). Fragment 3 comprises the internal portion of RIN4 between sites I and II (underlined in black). (C) RIN4(F9A) mutant protein is only cleaved at site II by AvrRpt2:HA. The resulting fragment (Fig 3C) comprises the N-terminus of RIN4(F9A) up to site II. (D) RIN4(F151A) mutant protein is only cleaved at site I by AvrRpt2:HA. RIN4(F151A) was incubated with AvrRpt2:HA and ROC1, resulting in two visible fragments ( Fig  3C) . Fragment 1 comprises the C-terminus of RIN4(F151A) up to site I and fragment 3 comprises the N-terminus. Peptides identified from fragment 1 are underlined in black, while those from fragment 3 are underlined in red.
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